Venture Technology Group Announces Collaborative Partnership with Mr Matt McCarthy, Manager, Global Investment and Innovation Incentives (Gi3) at Deloitte
Dr Dennis Feeney, Founder and Chair of Venture Technology Group (VTG) and VTG Search is pleased to announce a collaborative partnership with Mr Matt McCarthy, Manager, Global Investment and Innovation Incentives (Gi3) at Deloitte. Matt’s experience and Deloitte’s global reach is anticipated to make a substantial contribution to the integrated offering of VTG to comprehensive and curated inbound and outbound technology development and commercialisation – people, projects and products.
About Matt McCarthy
Matt is a R&D Tax Incentive and innovation specialist with key specialisation in Science Technology Engineering and Mathematics (STEM) based innovations. Being awarded the top specialist consultant in Australia in the Accountants Daily 30 under 30 awards 2021, Matt’s passion lies in bridging the gap between scientific ideation, research and commercialisation through Government funding and strategy for start-ups, SMEs and multi-national corporations alike.
Leveraging a Bachelor of Medical Science majoring in Neuroscience, a Master of Commerce majoring in Accounting and Finance, and being a qualified Chartered Accountant, Matt develops a deep understanding of client scientific and financial endeavours, allowing the unique formulation of holistic strategies and the optimisation of R&D and innovation funding opportunities.
Matt boasts extensive experience in the delivery of specialist R&D and related innovation tax advice in the Life Sciences sector, ranging from all phases of clinical trial activity, medical device development, pharmaceutical and alternative medicine formulation, to genetic mutation studies to name a few. This includes additional considerations for inbound foreign companies, such as obtaining successful outcomes for numerous R&D Overseas Advance Finding applications, resulting in extended funding certainty based on collaboration with, and upfront review by, the relevant R&D authorities.
Matt and his team in Global Investment and Innovation Incentives can assist with a broad range of services, including: preparation and advisory for the Research and Development Tax Incentive (RDTI); RDTI Overseas Finding application preparation; Early Stage Innovation Company incentives advisory; Grant application preparation and advisory; Inbound company requirements and appointments; Tax structuring and preparation, including application of the Hybrid Mismatch rules; transfer Pricing advisory and documentation preparation
About Deloitte Life Sciences
Deloitte’s specialist Life Sciences team is comprised of members with Bachelor, Master and PhD degrees in Biotechnology and Life Sciences. Through their industry focussed work experience, team members have strong relationships with the breadth of the key contributors along the therapeutic development pathway. Our vast array of experts specialize in fields, such as; Health Consulting, R&D Tax, Transfer Pricing, Corporate and International Tax, and life sciences and biotechnology Valuations and M&A. This, combined with our deep life sciences specialization and experience, enables us to understand client’s technology, the development lifecycle, the Australian life science ecosystem and client’s options for commercialisation which allows us to speak our client’s language and share our deep sector insights.
Today’s environment of accelerating change requires creative problem-solving generated by the fusion of different disciplines. Deloitte’s multi-dimensional approach addresses the breadth of perspective needed to deliver breakthrough solutions. The synergies created through having a committed and aligned multi- disciplined service team enables a streamlined process to be provided and establishes a harmonised risk profile for your tax matters and company advice.